NattoPharma (NATTO)

[FeitaInc]

Det virker som mr Bohan og co kjører et høyt spill. Jeg får for deres del inderlig håpe at alle avtaler de har gjort tåler dagens lys. Om det ikke er tilfelle kan de, ikke ulikt noen tidligere presidenter i USA, gå en spennende tid i møte.

Jeg vurderer tilbudet fra Lesaffre på 35 kroner pr. aksje som å være både i aksjonærfellesskapets og NattoPharmas interesser. Derfor ønsker jeg å bidra til at transaksjonen gjennomføres. Det på denne bakgrunn at TG Montgomery har kjøpt aksjene til kurs 38 kroner. Dette er en vurdering TGM og jeg har gjort, og en beslutning TGM og jeg har tatt som aksjonær i NattoPharma, svarer Bohan.

Dette er misforstått. Som styreleder er han insatt for å representere eiernes interesse mellom generalforsamling. Når han snakker om NattoPharma sine interesser så kan han kun uttale seg på sine egne veier, som en stor aksjonær. Han kan ikke vektlegge NattoPharma sin fremtid med mindre han har fått det klare mandatet av et flertall av aksjonærene. Å ha fått en preaksept på >50% er ikke det samme som å ha fått dette mandatet, da styret overhode ikke har presentert noe underlag for anbefalingen sin eller noe fra strategic review, og således ikke har gitt den enkelte aksjonær et likt grunnlag å ta en beslutning som kunne ha resultert i det mandatet. Personlig føler jeg nesten at jeg vet mindre om “strategic review” prosessen nå enn jeg gjorde før Kjetil annonserte den.

Det var noe han fra TG Montgomery sa til meg på telefonen som har irritert meg litt, og det var at ABG Sundal Collier hadde sett etter industrielle oppkjøpere siden dag en, og hatt møter med flere. (jeg mener ihvertfall han sa det.) da svarte jeg at det var akkurat det motsatte av det Kjetil har kommunisert, altså at fokus var på å se på verdier og hvordan maksimere de, og ikke ha fokus på å selge selskapet.

jeg har sagt det før og jeg sier det gjerne igjen; en ekstraordinær generalforsamling hadde nok ikke vært dum.

[holmes]

Ja, hverken Bohan eller Ramsøy gir noen gode svar i artikkelen. Slik jeg tolker det er Ramsøy sitt svar også feil siden han bare siterer melding fra 15. februar og ikke nevner tilleggene den 25. februar der de har forpliktet seg til å selge selv om det kommer høyere bud fra andre.

[FeitaInc]

Og Kappa må virkelig komme på banen om de vil. Nå forsøker de å være på begge sider av gjerdet i alt de kommuniserer, som fremstår som alt annet enn troverdig.

å gå ut med:

–Vi snakker med våre rådgivere. Det er merkelig at NattoPharma ikke forsøker å få maksimal verdi ut av selskapet i budprosessen, i og med at de fortsatt ikke kontakter oss som er største eier, sier Åberg til Finansavisen.

etter å ha kommet med et bud på 12,75 kr for et halvt år siden… Hadde jeg vært eieren av de som kjøpte Kappa hadde jeg enten sparket de som kjørte den prosessen eller trukket de noen år i lønn og bonuser. Det eneste andre alternativet hvor det ikke gir mening er at de ønsker å drive opp prisen på selskapet sånn at en annen kjøper overbetaler masse, og med det svekker sin egen posisjon. om det er strategien hadde jeg gitt de bonus.

[FeitaInc]

@holmes

ikke nevner tilleggene den 25. februar der de har forpliktet seg til å selge selv om det kommer høyere bud fra andre.

Jeg hadde ikke blitt overrasket om den endringen var drevet frem etter whealing dealing med Bohan og gjengen. “om dere gjør det sånn, capper dere muligheten for økte kostnader for de som kjøper.”

[holmes]

Investor	Number of shares	% of top 20	% of total	Type	Country
PRO AS	2,701,310	15.89%	13.61%	Comp.	NOR
KAPPA BIOSCIENCE AS	2,373,475	13.96%	11.96%	Comp.	NOR
TG MONTGOMERY AS	1,735,122	10.21%	8.74%	Comp.	NOR
EUROCLEAR BANK S.A./N.V.	1,373,176	8.08%	6.92%	Nom.	BEL
BOHAN & CO AS	1,298,455	7.64%	6.54%	Comp.	NOR
SVENSKA HANDELSBANKEN AB	1,289,577	7.59%	6.50%	Nom.	SWE
AVANZA BANK AB	1,187,574	6.99%	5.98%	Nom.	SWE
CARNEGIE AS MEGLERKONTO INNLAND	997,710	5.87%	5.03%	Meg.	NOR
DNB NOR BANK ASA EGENHANDELSKONTO	533,550	3.14%	2.69%	Comp.	NOR
JAN FR. BJERKENES HOLDING AS	474,827	2.79%	2.39%	Comp.	NOR
DNB NOR MARKETS, AKSJEHAND/ANALYSE MEGLERKONTO INNLAND	410,243	2.41%	2.07%	Meg.	NOR
NIELSEN TRYGVE	365,000	2.15%	1.84%	Priv.	NOR
THE BANK OF NEW YORK MELLON SA/NV	350,359	2.06%	1.77%	Nom.	FRA
RATUSINSKA PATRYCJA KAROLINA	350,000	2.06%	1.76%	Priv.	POL
GOLDMAN SACHS INT. - EQUITY	349,079	2.05%	1.76%	Comp.	GBR
CINCO INVEST AS	300,000	1.76%	1.51%	Comp.	NOR
ØYEN ERIK	275,000	1.62%	1.39%	Priv.	NOR
NORDNET BANK AB	267,995	1.58%	1.35%	Nom.	SWE
NICOLINE INVEST AS	200,000	1.18%	1.01%	Comp.	NOR
GOLDMAN SACHS BANK EUROPE SE	164,820	0.97%	0.83%	Nom.	DEU
Total number owned by top 20	16,997,272	100%	85.66%
Total number of shares	19,843,433		100%

Last updated 03.03.2021

[holmes]

[holmes]

Investor	Number of shares	% of top 20	% of total	Type	Country
PRO AS	2,861,310	16.76%	14.42%	Comp.	NOR
KAPPA BIOSCIENCE AS	2,676,185	15.67%	13.49%	Comp.	NOR
TG MONTGOMERY AS	1,735,122	10.16%	8.74%	Comp.	NOR
EUROCLEAR BANK S.A./N.V.	1,373,191	8.04%	6.92%	Nom.	BEL
BOHAN & CO AS	1,298,455	7.60%	6.54%	Comp.	NOR
SVENSKA HANDELSBANKEN AB	1,289,577	7.55%	6.50%	Nom.	SWE
AVANZA BANK AB	1,187,022	6.95%	5.98%	Nom.	SWE
DNB NOR BANK ASA EGENHANDELSKONTO	843,778	4.94%	4.25%	Comp.	NOR
CARNEGIE AS MEGLERKONTO INNLAND	719,928	4.22%	3.63%	Meg.	NOR
JAN FR. BJERKENES HOLDING AS	474,827	2.78%	2.39%	Comp.	NOR
NIELSEN TRYGVE	365,000	2.14%	1.84%	Priv.	NOR
THE BANK OF NEW YORK MELLON SA/NV	350,359	2.05%	1.77%	Nom.	FRA
RATUSINSKA PATRYCJA KAROLINA	350,000	2.05%	1.76%	Priv.	POL
CINCO INVEST AS	300,000	1.76%	1.51%	Comp.	NOR
ØYEN ERIK	275,000	1.61%	1.39%	Priv.	NOR
NORDNET BANK AB	251,473	1.47%	1.27%	Nom.	SWE
GOLDMAN SACHS INT. - EQUITY	211,305	1.24%	1.06%	Comp.	GBR
NICOLINE INVEST AS	200,000	1.17%	1.01%	Comp.	NOR
GOLDMAN SACHS BANK EUROPE SE	176,095	1.03%	0.89%	Nom.	DEU
MARKIEWICZ JAN MARIAN	137,500	0.81%	0.69%	Priv.	NOR
Total number owned by top 20	17,076,127	100%	86.05%
Total number of shares	19,843,433		100%

Last updated 04.03.2021

[holmes]

@holmes

|KAPPA BIOSCIENCE AS|2,676,185|15.67%|13.49%|Comp.|NOR

@holmes

|DNB NOR BANK ASA EGENHANDELSKONTO|843,778|4.94%|4.25%|Comp.|NOR

@holmes

|CARNEGIE AS MEGLERKONTO INNLAND|719,928|4.22%|3.63%|Meg.|NOR

13.49+4.25+3.63 =21.37

[holmes]

Investor	Number of shares	% of top 20	% of total	Type	Country
PRO AS	2,861,310	16.77%	14.42%	Comp.	NOR
KAPPA BIOSCIENCE AS	2,676,185	15.69%	13.49%	Comp.	NOR
TG MONTGOMERY AS	1,735,122	10.17%	8.74%	Comp.	NOR
EUROCLEAR BANK S.A./N.V.	1,373,191	8.05%	6.92%	Nom.	BEL
BOHAN & CO AS	1,298,455	7.61%	6.54%	Comp.	NOR
SVENSKA HANDELSBANKEN AB	1,289,577	7.56%	6.50%	Nom.	SWE
AVANZA BANK AB	1,118,876	6.56%	5.64%	Nom.	SWE
DNB NOR BANK ASA EGENHANDELSKONTO	859,438	5.04%	4.33%	Comp.	NOR
CARNEGIE AS MEGLERKONTO INNLAND	719,928	4.22%	3.63%	Meg.	NOR
JAN FR. BJERKENES HOLDING AS	474,827	2.78%	2.39%	Comp.	NOR
THE BANK OF NEW YORK MELLON SA/NV	381,734	2.24%	1.92%	Nom.	FRA
NIELSEN TRYGVE	365,000	2.14%	1.84%	Priv.	NOR
RATUSINSKA PATRYCJA KAROLINA	350,000	2.05%	1.76%	Priv.	POL
CINCO INVEST AS	300,000	1.76%	1.51%	Comp.	NOR
ØYEN ERIK	275,000	1.61%	1.39%	Priv.	NOR
THE BANK OF NEW YORK MELLON SA/NV	237,680	1.39%	1.20%	Nom.	GBR
NORDNET BANK AB	229,882	1.35%	1.16%	Nom.	SWE
NICOLINE INVEST AS	200,000	1.17%	1.01%	Comp.	NOR
GOLDMAN SACHS INT. - EQUITY	176,204	1.03%	0.89%	Comp.	GBR
MARKIEWICZ JAN MARIAN	137,500	0.81%	0.69%	Priv.	NOR
Total number owned by top 20	17,059,909	100%	85.97%
Total number of shares	19,843,433		100%

Last updated 05.03.2021

[holmes]

Investor	Number of shares	% of top 20	% of total	Type	Country
PRO AS	2,861,310	16.49%	14.42%	Comp.	NOR
KAPPA BIOSCIENCE AS	2,676,185	15.42%	13.49%	Comp.	NOR
TG MONTGOMERY AS	1,735,122	10.00%	8.74%	Comp.	NOR
EUROCLEAR BANK S.A./N.V.	1,373,191	7.91%	6.92%	Nom.	BEL
BOHAN & CO AS	1,298,455	7.48%	6.54%	Comp.	NOR
SVENSKA HANDELSBANKEN AB	1,289,577	7.43%	6.50%	Nom.	SWE
AVANZA BANK AB	1,102,848	6.36%	5.56%	Nom.	SWE
DNB NOR BANK ASA EGENHANDELSKONTO	993,793	5.73%	5.01%	Comp.	SWE
CARNEGIE AS MEGLERKONTO INNLAND	719,928	4.15%	3.63%	Meg.	NOR
JAN FR. BJERKENES HOLDING AS	474,827	2.74%	2.39%	Comp.	NOR
THE BANK OF NEW YORK MELLON SA/NV	464,390	2.68%	2.34%	Nom.	FRA
THE BANK OF NEW YORK MELLON SA/NV	413,884	2.39%	2.09%	Nom.	GBR
NIELSEN TRYGVE	365,000	2.10%	1.84%	Priv.	NOR
RATUSINSKA PATRYCJA KAROLINA	350,000	2.02%	1.76%	Priv.	POL
CINCO INVEST AS	300,000	1.73%	1.51%	Comp.	NOR
ØYEN ERIK	275,000	1.58%	1.39%	Priv.	NOR
NORDNET BANK AB	218,232	1.26%	1.10%	Nom.	SWE
NICOLINE INVEST AS	200,000	1.15%	1.01%	Comp.	NOR
MARKIEWICZ JAN MARIAN	137,500	0.79%	0.69%	Priv.	NOR
MARÅS EINAR	104,000	0.60%	0.52%	Priv.	NOR
Total number owned by top 20	17,353,242	100%	87.45%
Total number of shares	19,843,433		100%

Last updated 08.03.2021

[TekBot]

Voluntary offer – offer document approved

Oslo Børs, in capacity as take-over supervisory authority, has approved offer set out in offer document dated 8 March 2021 in respect of:

Voluntary offer to acquire the shares in NattoPharma ASA made by Compagnie des Levures Lesaffre.
…

Vis børsmeldingen

Offer price: NOK 35 per share

Offer period: From and including 9 March 2021 to 16:30 hours (CET) on 23 March 2021 (subject to extension)

Receiving agent: Nordea Bank Abp, filial i Norge

Kilde

[TekBot]

NattoPharma ASA: Lesaffre is launching recommended voluntary cash offer for NattoPharma at NOK 35 per share

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA,
CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE
WOULD BE UNLAWFUL.
…

Vis børsmeldingen

Oslo, 9 March 2021: Following the announcement on 15 February 2021 regarding a
contemplated offer to acquire all outstanding shares of NattoPharma ASA
(“NattoPharma” or the “Company”), Compagnie des Levures Lesaffre (“Lesaffre” or
the “Offeror”) is today launching a recommended voluntary cash offer (the
“Offer”) for all of NattoPharma’s outstanding shares against a consideration in
cash of NOK 35.00 per share (the “Offer Price”).

Reference is made to the approval by the Oslo Stock Exchange of the offer
document dated 8 March 2021 (the “Offer Document”) prepared in connection with
the Offer. The shareholders of NattoPharma may tender their shares on the
conditions of the voluntary recommended offer from today, 9 March 2021, and
until 23 March 2021 at 16:30 hours (CET), subject to extension.

·
The Board of Directors of NattoPharma unanimously recommends the Offer, which
values the total share capital of NattoPharma at approximately NOK 736 million
on a fully diluted basis (excluding treasury shares). The Offer Price of NOK 35
per share represents a 65%, 82% and 88% premium to the volume-weighted average
closing price (“VWAP”) of the Company for the one-month, three-month and six
-month period prior to 12 February 2021 respectively. Further, the Offer Price
represents a 133% premium to the closing price on 2 June 2020, being the date
when the Board of Directors initiated its strategic review. The Offer represents
a 42% premium to the to the closing price on 12 February 2021.

·
Shareholders representing approximately 59.39% of the shares (on a fully diluted
basis, excluding treasury shares) have already provided irrevocable pre
-acceptances which only provide for a right to be withdrawn if the Offeror has
not publicly announced that the conditions for completion of the Offer have been
satisfied or waived by the Offeror by 31 May 2021. Furthermore, the Offeror has
received undertakings from the option holders in NattoPharma whereby the option
holders have undertaken to exercise their options and to sell the option shares
to the Offeror at the Offer Price. These undertakings represent approximately
5.71% of the shares (on a fully diluted basis excluding treasury shares). The
Offeror has also purchased 562,074 shares in the market. The total number of
shares comprised of the irrevocable pre-acceptances, the undertakings of the
option holders and the Offeror’s own shares represents 67.77% of the shares in
NattoPharma on a fully diluted basis excluding treasury shares. The complete
terms and conditions for the Offer, including procedures for how to accept the
Offer and detailed information regarding settlement, are set out in the Offer
Document.

·
The Offer period commences on Tuesday 9 March 2021 and expires on Monday 23
March 2021 at 16:30 hours (CET). The Offeror may in its sole discretion extend
the offer period (one or several times), but the offer period will in no event
be extended beyond 18 May 2021 at 16:30 hours (CET).

In recommending the Offer, the Board of Directors of NattoPharma comments:
“Having carefully reviewed the terms and conditions of the Offer, and in
consideration of the evaluation provided by the Company’s advisors and the
statement by the independent expert, the Board has concluded that the
consideration offered for the shares in the Company is attractive.”

KWC AS has provided an independent statement in accordance with § 6-16 of the
Norwegian Securities Trading Act inter alia concluding that: “These analyses
provide substantial support that the Offer price provides NattoPharma
shareholders with some of the value of synergies that are expected to accrue to
the combined Lesaffre - NattoPharma business” and that “[t]he terms of the Offer
are fair from a financial point of view and the Offer Price of NOK 35 per share
represents a full and fair arm’s length price for all the outstanding shares of
NattoPharma.”

The Offer Document, containing the full terms and conditions of the Offer will,
subject to regulatory restrictions in certain jurisdictions, be sent today, 9
March 2021, to all shareholders in NattoPharma whose address appears in
NattoPharma’s share register in the Norwegian Central Securities Depositary
(VPS) as of 8 March 2021.

As further detailed and specified in the Offer Document, the completion of the
Offer will be subject to certain conditions being satisfied or waived by the
Offeror (acting in its sole discretion).

The Offer Document is, subject to regulatory restrictions in certain
jurisdictions, available at www.nattopharma.com.

Background for the Offer

The Offer is made by Compagnie des Levures Lesaffre, a direct 98.57% owned
subsidiary of Lesaffre & Cie.

Lesaffre is a key global player in fermentation for more than a century, with a
revenue of more than 2 billion euro, and established on all continents, counts
10,700 employees and more than 70 nationalities. On the strength of this
experience and diversity, Lesaffre works with customers, partners and
researchers to find ever more relevant answers to the needs of food, health,
naturalness and respect for our environment. Thus, every day, Lesaffre explores
and reveals the infinite potential of microorganisms. To nourish 10 billion
people, in a healthy way, in 2050 by making the most of our planet’s resources
is a major and unprecedented issue. Lesaffre believes that fermentation is one
of the most promising answers to this challenge.

Lesaffre believes that joining forces with NattoPharma would be beneficial for
both companies. Their geographic footprint are complementary and joining forces
would create a truly global company that would offer a documented and innovative
science-backed approach with the solid sourcing and applications. The combined
entity will be well equipped to make the best use of the opportunity in a market
that has seen rapid expansion in most parts of the world.

Reference is also made to the statement from NattoPharma’s CEO Kjetil Ramsøy on
15 February 2021 where he stated the following:

“We are impressed with Lesaffre´s track record and global reach and we are
confident that partnering up with their team will enable us to reach the next
level. We are excited about the opportunities ahead and we will continue
developing and delivering world class products to our joint customer base.”

The Offer Document contains further details regarding the Offer, and the
shareholders of NattoPharma are advised to review the Offer Document in detail.
The Offer and the distribution of this announcement and other information in
connection with the Offer may be restricted by law in certain jurisdictions and
the Offer is not made in any jurisdiction where the making of the Offer would
not be in compliance with the laws of such jurisdiction. The Offeror assumes no
responsibility in the event there is a violation by any person of such
restrictions. Persons into whose possession this announcement or such other
information should come are required to inform themselves about and to observe
any such restrictions. This announcement does not in itself constitute an offer.
The Offer is made in the Offer Document and can only be accepted pursuant to the
terms of such document.

Rothschild is acting as financial adviser to Lesaffre and the Offeror and Nordea
Bank Abp, filial i Norge, is acting as receiving agent. Advokatfirmaet
Thommessen AS is acting as the Norwegian legal adviser, and Linklaters is acting
as the French legal adviser, to Lesaffre and the Offeror in connection with the
Offer.

ABG Sundal Collier ASA is acting as financial adviser and Advokatfirmaet CLP DA
is acting as Norwegian legal adviser to NattoPharma.

For further information, please contact:
NattoPharma:

NattoPharma ASA
Att: Kjetil RamsøyTelephone: +47 906 12 943
Email: kjetil.ramsoy@nattopharma.com

Lesaffre:

Agence Wellcom
Att: Valérie Lassale/Chloe Bencivengo
Telephone: +33(0)1 46 34 60 60
Email: lesaffre@wellcom.fr

About NattoPharma:
NattoPharma is a public limited liability company listed on Euronext Expand Oslo
and is headquartered in Oslo. NattoPharma is the world’s leader in vitamin K2
research and development, and is the owner and exclusive distributer of MenaQ7®
Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with
guaranteed actives and stability, clinical substantiation, and international
patents granted and pending, and now the new MenaQ7® Full Spectrum, which
delivers menaquinones 6, 7, 8, and 9. The company has a multi-year research and
development program to substantiate and discover the health benefits of vitamin
K2 for applications in the marketplace for functional food and dietary
supplements.

About Lesaffre:

A key global player in fermentation for more than a century, Lesaffre, with a
2.2 billion euro turnover, and established on all continents, counts 10,700
employees and more than 85 nationalities. On the strength of this experience and
diversity, we work with customers, partners and researchers to find ever more
relevant answers to the needs of food, health, naturalness and respect for our
environment. Thus, every day, we explore and reveal the infinite potential of
microorganisms.

To nourish 10 billion people, in a healthy way, in 2050 by making the most of
our planet’s resources is a major and unprecedented issue. We believe that
fermentation is one of the most promising answers to this challenge.

Important notice:

The Offer and the distribution of this announcement and other information in
connection with the Offer may be restricted by law in certain jurisdictions.
Lesaffre and the Offeror assume no responsibility in the event there is a
violation by any person of such restrictions. Persons into whose possession this
announcement or such other information should come are required to inform
themselves about and to observe any such restrictions.

THE OFFER WILL NOT BE MADE IN ANY JURISDICTION IN WHICH MAKING OF THE OFFER
WOULD NOT BE IN COMPLIANCE WITH THE LAWS OF SUCH JURISDICITON. THIS ANNOUNCEMENT
DOES NOT IN ITSELF CONSTITUTE AND OFFER. THE OFFER WILL ONLY BE MADE ON THE
BASIS OF THE OFFER DOCUMENT AND CAN ONLY BE ACCEPTED PURSUANT TO THE TERMS OF
SUCH DOCUMENT.

The Offer is subject to disclosure and procedural requirements of the Kingdom of
Norway which are different from those in the United States. In addition, the
payment and settlement procedures with respect to the Offer will comply with the
relevant Norwegian rules, which differ from United States payment and settlement
procedures.

This information is subject to the disclosure requirements of NattoPharma
pursuant to section 5 -12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

NattoPharma ASA is launching cash tender offer to acquire 100% of the shares of Kaydence Pharma AS at an offer price of NOK 5 per share

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA,
CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE
WOULD BE UNLAWFUL.
…

Vis børsmeldingen

Oslo, Norway (9 March 2021) - Reference is made to the stock exchange
disclosures by NattoPharma ASA (“NattoPharma”) on 15 February 2021 regarding
NattoPharma entering into a transaction agreement (the “Transaction Agreement”)
with Compagnie des Levures Lesaffre (“Lesaffre”) under which (i) Lesaffre will
launch a recommended voluntary cash tender offer (the “NattoPharma Offer”) to
acquire 100% of the shares of NattoPharma, and (ii) NattoPharma will launch a
cash tender offer (the “Kaydence Offer”) to acquire 100% of the shares (the
“Shares”) of Kaydence Pharma AS (“Kaydence Pharma”) at an offer price of NOK 5
per Share (“Offer Price”).

Oslo Stock Exchange has on 8 March 2021 approved the offer document prepared by
Lesaffre in connection with the NattoPharma Offer.

Therefore, NattoPharma is today launching the Kaydence Offer for all of the
Shares in Kaydence Pharma at the Offer Price of NOK 5 per Share. The
shareholders of Kaydence may tender their shares on the terms and conditions of
the Kaydence Offer from today, 9 March 2021, and until 23 March 2021 at 16:30
hours (CET), subject to extension (“Offer Period”).

NattoPharma currently owns 3,000,000 Shares in Kaydence Pharma, equivalent to
54.14 % of Kaydence Pharma’s equity. Further, NattoPharma has received
irrevocable commitments to accept the Kaydence Offer from shareholders which
will bring NattoPharma’s ownership to 80.9% of the Shares in Kaydence Pharma,
including all shareholders represented at the Board of Directors and the top
management of NattoPharma and Kaydence Pharma.

About the Kaydence Offer:

· The Offer Price of NOK 5 will be settled in cash.
· The Offer period commences on Tuesday 9 March 2021 and expires on Monday 23
March 2021 at 16:30 hours (CET). NattoPharma may in its sole discretion extend
the offer period (one or several times), but the offer period will in no event
be extended beyond 18 May 2021 at 16:30 hours (CET).
· Completion of the Kaydence Offer is subject to Lesaffre completing the
NattoPharma Offer.

The Offer will not contain any conditions as to financing or due diligence.

The complete details of the Kaydence Offer, including all terms and conditions,
are included in an Offer letter (the “Offer Letter”) to be sent to the Company’s
shareholders following this announcement.

This notification does not in itself constitute an offer. The Kaydence Offer
will only be made on the basis of the Offer Letter and can only be accepted
pursuant to the terms of the Offer Letter. The Kaydence Offer will not be made
in any jurisdiction in which the making of the Kaydence Offer would not be in
compliance with the laws of such jurisdiction.

ABG Sundal Collier ASA is acting as financial adviser and Advokatfirmaet CLP DA
is acting as Norwegian legal adviser to NattoPharma.

For further information, please contact:
NattoPharma:

NattoPharma ASA
Att: Kjetil Ramsøy
Telephone: +47 906 12 943
Email: kjetil.ramsoy@nattopharma.com

About Kaydence Pharma:
Early stage pharmaceutical company focused on the development of menaquinone-7
(MQ-7, a form of vitamin K2) for the treatment of vascular calcification.

About NattoPharma:
NattoPharma is a public limited liability company listed on Euronext Expand Oslo
and is headquartered in Oslo. NattoPharma is the world’s leader in vitamin K2
research and development, and is the owner and exclusive distributer of MenaQ7®
Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with
guaranteed actives and stability, clinical substantiation, and international
patents granted and pending, and now the new MenaQ7® Full Spectrum, which
delivers menaquinones 6, 7, 8, and 9. The company has a multi-year research and
development program to substantiate and discover the health benefits of vitamin
K2 for applications in the marketplace for functional food and dietary
supplements.

This information is subject to the disclosure requirements of NattoPharma
pursuant to section 5 -12 of the Norwegian Securities Trading Act.

Kilde

[Savepig]

Dette blir vel sluttspillet?

[Christian]

Spørsmålet er jo hva Kappa har tenkt å gjøre. Tviler på at de selger på 35? Hvis de ikke får et bedre tilbud, så tenker jeg de bare sitter med aksjene. Lurer på hva @holmes har tenkt å gjøre

[holmes]

Ser vel sånn ut

[holmes]

Kommer til å takke ja om ikke det skjer noe uventet, mottrekk fra Kappa

Har ikke behov for pengene og tror kanskje nok kan gå litt mot sek de neste ukene så venter ut de siste ukene.

[Christian]

Kappa må jo evt kjøpe aksjene fra Lesaffre, så tviler på at de egentlig får gjort noe særlig her…

[holmes]

Ja, det blir en veldig spesiell situasjon, men nesten bare to eiere, Kappa kanskje tror de kan få mer ved å bli kjøpt ut senere på en høyere pris.

[Christian]

Jeg tror jo Kappa godt kan få en mye høyere pris om 2-3 år, men så er spørsmålet hva slags kromspring Lesaffre kan finne på å gjøre som majoritetseier.